½ÃÀ庸°í¼­
»óǰÄÚµå
1621593

¼¼°èÀÇ ÀΰøÇ÷°ü ½ÃÀå : ¿øÀÚÀç, Á¦Ç°, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚº° - Àü¸Á(2025-2030³â)

Vascular Graft Market by Raw Material (Biological Materials, Polyester, Polytetrafluoroethylene), Product (Coronary Artery By-Pass Graft, Endovascular Stent Graft, Hemodialysis Access Graft), Application, End-User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 182 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

ÀΰøÇ÷°ü ½ÃÀåÀº 2023³â¿¡ 35¾ï 1,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â¿¡´Â 37¾ï 7,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç CAGR 7.39%·Î ¼ºÀåÇØ 2030³â¿¡´Â 57¾ï 9,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÀΰøÇ÷°üÀº Áúº´À̳ª ¿Ü»óÀ¸·Î ÀÎÇØ ¼Õ»óµÈ Ç÷°üÀÇ ÀϺθ¦ ´ëü, ¿ìȸ, º¹±¸ÇÏ´Â µ¥ »ç¿ëµÇ´Â ÀÇ·á±â±âÀÔ´Ï´Ù. ÀÌ ½ÃÀå¿¡´Â ÇÕ¼º, »ý¹°ÇÐÀû, »ýÇÕ¼º ÀΰøÇ÷°üÀÌ Æ÷ÇÔµÇ¸ç °ü»óµ¿¸Æ ¿ìȸ, Ç÷¾× Åõ¼® Á¢±Ù, ¸»Ãʵ¿¸Æ Áúȯ µî ´Ù¾çÇÑ ¿ëµµ·Î »ç¿ëµË´Ï´Ù. ÀΰøÇ÷°üÀÇ Çʿ伺Àº ÁÖ·Î ½ÉÇ÷°ü ÁúȯÀÇ À¯º´·ü Áõ°¡, Åõ¼®ÀÌ ÇÊ¿äÇÑ ¸»±â ½ÅÀå ÁúȯÀÇ À¯º´·ü Áõ°¡, Ç÷°ü Áúȯ¿¡ Ãë¾àÇÑ ³ëÀÎ Àα¸ Áõ°¡·Î ÀÎÇØ ¹ß»ýÇÕ´Ï´Ù. ÃÖÁ¾ »ç¿ë ºÐ¾ß¿¡´Â ÀÌ·¯ÇÑ ½Ã¼úÀÌ ÀÚÁÖ ÀÌ·ç¾îÁö´Â º´¿ø, Ŭ¸®´Ð, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC) µîÀÌ Æ÷ÇԵ˴ϴÙ. ÀΰøÇ÷°ü ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä ¼ºÀå ¿äÀÎÀ¸·Î´Â ÀÌ½Ä Àç·áÀÇ ±â¼ú ¹ßÀü, ÃÖ¼Òħ½ÀÀû ¼ö¼ú¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡, À¯¸®ÇÑ »óȯ ½Ã³ª¸®¿À µîÀÌ ÀÖ½À´Ï´Ù. ±×·¯³ª ÀÌ½Ä ¼ö¼ú¿¡ µû¸¥ ³ôÀº ºñ¿ë, ÀÌ½ÄÆí ÆÄ¼Õ ¹× °¨¿°°ú °°Àº ÀáÀçÀû ÇÕº´Áõ, ¾ö°ÝÇÑ ±ÔÁ¦ ȯ°æ µîÀÌ ½ÃÀå ¼ºÀåÀÇ Á¦¾à¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ ºÐ¾ßÀÇ °³¹ß ±âȸ·Î´Â »ýüÀûÇÕ¼º°ú Ç×Ç÷Àü¼ºÀ» °­È­ÇÑ Â÷¼¼´ë ÀÌ½ÄÆí °³¹ß, ÀÇ·á ÀÎÇÁ¶ó ÅõÀÚ°¡ È®´ëµÇ°í ÀÖ´Â ½ÅÈï±¹ ½ÃÀå ÁøÃâ µîÀ» ²ÅÀ» ¼ö ÀÖ½À´Ï´Ù. Çõ½ÅÀûÀÎ ¿¬±¸ ºÐ¾ß·Î´Â »ýºÐÇØ¼º ÀΰøÇ÷°ü ¿¬±¸, Á¶Á÷°øÇÐ ±â¼ú °³¼±, 3D ÇÁ¸°ÆÃ ±â¼úÀ» Ȱ¿ëÇÏ¿© ȯÀÚ °³°³ÀÎÀÇ ÇØºÎÇÐÀû ±¸Á¶¿¡ ¸Â´Â ¸ÂÃãÇü ÀΰøÇ÷°ü Á¦ÀÛ µîÀÌ ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±â¼ú µ¿ÇâÀ» ¼±Á¡Çϱâ À§ÇÑ ¿¬±¸°³¹ß¿¡ ÀÖ¾î ¹ÙÀÌ¿ÀÅØ ±â¾÷°úÀÇ Çù·Â °ü°è¸¦ ¸ð»öÇÒ °¡´É¼ºµµ ÀÖ½À´Ï´Ù. ÀΰøÇ÷°ü ½ÃÀåÀº °æÀïÀÌ Ä¡¿­ÇÑ ½ÃÀåÀ̸ç, ÁÖ¿ä ±â¾÷µéÀº Á¦Ç° °³¹ß ¹× Àü·«Àû Á¦ÈÞ¿¡ ÅõÀÚÇÏ¸ç ¼¼°è ÀÔÁö¸¦ °­È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±âȸ¸¦ Ȱ¿ëÇϰíÀÚ ÇÏ´Â ±â¾÷µéÀº ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©¸¦ È¿À²ÀûÀ¸·Î Ȱ¿ëÇϰí, ºñ¿ë È¿À²ÀûÀÎ Á¦Á¶ °øÁ¤, ½ÂÀÎ ¹× Ãâ½Ã ÀÏÁ¤ °£¼ÒÈ­, ´Ù¾çÇÑ ¿Ü°úÀû ¼ö¼ú ¿ä±¸¿¡ ºÎÇÕÇÏ´Â Á¦Ç° Æ÷Æ®Æú¸®¿À¸¦ È®ÀåÇÏ´Â µ¥ ÁýÁßÇØ¾ßÇÒ °ÍÀÔ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ(2023³â) 35¾ï 1,000¸¸ ´Þ·¯
ÃßÁ¤ ¿¬µµ(2024³â) 37¾ï 7,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2030³â) 57¾ï 9,000¸¸ ´Þ·¯
CAGR(%) 7.39%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â ÀΰøÇ÷°ü ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

ÀΰøÇ÷°ü ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ëÀ» ÅëÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ º¯È­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«Àû ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • Àü ¼¼°è »ýȰ½À°üº´ À¯º´·ü Áõ°¡
    • Àúħ½ÀÀû ¼ö¼ú¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡
    • ÀΰøÇ÷°ü ÀÓ»ó½ÃÇè °Ç¼ö Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ÀΰøÇ÷°ü ½Ã¼úÀÇ ³ôÀº Ä¡·á ºñ¿ë
  • ½ÃÀå ±âȸ
    • ÀΰøÇ÷°ü µðÀÚÀÎ ¹× ¼º´É Çâ»ó
    • Á¶Á÷°øÇÐÀû ÀΰøÇ÷°ü °³¹ß
  • ½ÃÀå °úÁ¦
    • ÀΰøÇ÷°ü °ü·Ã °¨¿°

Porter's Five Forces: ÀΰøÇ÷°ü ½ÃÀå Ž»öÀ» À§ÇÑ Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. PorterÀÇ Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ÀΰøÇ÷°ü ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ÀΰøÇ÷°ü ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® ÀΰøÇ÷°ü ½ÃÀå °æÀï»óȲ ÆÄ¾Ç

ÀΰøÇ÷°ü ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­ ¹× ÅëÇÕ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ÀΰøÇ÷°ü ½ÃÀå¿¡¼­°ø±Þ¾÷ü ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ÀΰøÇ÷°ü ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ ÀΰøÇ÷°ü ½ÃÀå ¼º°øÀÇ ±æÀ» ±×¸³´Ï´Ù.

ÀΰøÇ÷°ü ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ÀÇ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ ±â¾÷Àº °æÀï ȯ°æÀÇ µµÀüÀ» ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ ü°è¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ÀΰøÇ÷°ü ½ÃÀå : ¿øÀç·áº°

  • »ý¹° Àç·á
    • Àΰ£ º¹Àç ¹× Á¦´ë Á¤¸Æ
    • Á¶Á÷°øÇÐ Àç·á
  • Æú¸®¿¡½ºÅ׸£
  • Æú¸®Åׯ®¶óÇ÷ç¿À·Î¿¡Æ¿·»
  • Æú¸®¿ì·¹Åº

Á¦7Àå ÀΰøÇ÷°ü ½ÃÀå : Á¦Ç°º°

  • °ü»óµ¿¸Æ ¿ìȸ¼ú
  • Ç÷°ü³» ½ºÅÙÆ® ±×·¡ÇÁÆ®
  • Ç÷¾× Åõ¼® ¾×¼¼½º ±×·¡ÇÁÆ®
  • ÁÖº¯±â±â ÀΰøÇ÷°ü

Á¦8Àå ÀΰøÇ÷°ü ½ÃÀå : ¿ëµµº°

  • µ¿¸Æ·ù
  • ½ÉÀåÇ÷°ü
  • ´ç´¢º´
  • ½ÅºÎÀü
  • Ç÷°ü Æó¼â

Á¦9Àå ÀΰøÇ÷°ü ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
  • º´¿ø

Á¦10Àå ¾Æ¸Þ¸®Ä«ÀÇ ÀΰøÇ÷°ü ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÀΰøÇ÷°ü ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦12Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÀΰøÇ÷°ü ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023³â
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • Abbott Laboratories
  • Affluent Medical
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • BIOVIC Sdn. Bhd.
  • Boston Scientific Corporation
  • Cardinal Health Inc.
  • Cook Medical, Inc.
  • Corcym S.r.l.
  • CryoLife, Inc.
  • Endologix Inc.
  • Getinge AB
  • Heart Medical Europe B.V.
  • Japan Lifeline Co., Ltd.
  • Lemaitre Vascular, Inc.
  • Medtronic PLC
  • Merit Medical Systems, Inc.
  • Perouse Medical SAS by Vygon SAS
  • Rua Life Sciences PLC
  • Shanghai Suokang Medical Implants Co. Ltd.
  • Terumo Corporation
  • Vascular Graft Solutions Ltd.
  • VUP Medical
  • W. L. Gore & Associates, Inc.
  • Xeltis B.V.
LSH 25.01.03

The Vascular Graft Market was valued at USD 3.51 billion in 2023, expected to reach USD 3.77 billion in 2024, and is projected to grow at a CAGR of 7.39%, to USD 5.79 billion by 2030.

Vascular grafts are medical devices used to replace, bypass, or repair sections of blood vessels that are damaged due to disease or traumatic injury. The scope of this market includes synthetic, biological, and biosynthetic vascular grafts, with applications spanning coronary artery bypass, hemodialysis access, and peripheral artery diseases. The necessity for vascular grafts is primarily driven by the rising prevalence of cardiovascular diseases, increasing incidence of end-stage renal diseases necessitating dialysis, and growing geriatric population who are more prone to vascular disorders. End-use segments include hospitals, clinics, and ambulatory surgical centers where such procedures are frequently performed. Key growth factors influencing the vascular graft market include technological advancements in graft materials, increasing preference for minimally invasive surgeries, and favorable reimbursement scenarios. However, limitations such as high costs associated with graft procedures, potential complications like graft failure or infection, and stringent regulatory environments pose challenges to market growth. Opportunities in this field include developing next-generation grafts with enhanced biocompatibility and anti-thrombogenic properties, and expanding into emerging markets with growing healthcare infrastructure investments. Innovative areas for research include exploring biodegradable vascular grafts, improving tissue engineering techniques, and leveraging 3D printing technology to tailor-make vascular grafts suited for individual patient anatomy. There is also potential in exploring collaborations with biotech firms for research and development to stay ahead of technology trends. The nature of the vascular graft market is competitive, with major players investing in product development and strategic partnerships to enhance their global presence. Businesses looking to capitalize on these opportunities should focus on cost-effective manufacturing processes, streamlining approval and launch timelines, and expanding product portfolios to meet diverse surgical needs, while navigating regulatory frameworks efficiently.

KEY MARKET STATISTICS
Base Year [2023] USD 3.51 billion
Estimated Year [2024] USD 3.77 billion
Forecast Year [2030] USD 5.79 billion
CAGR (%) 7.39%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Vascular Graft Market

The Vascular Graft Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of lifestyle-related disorders globally
    • Growing preference for minimally invasive procedures
    • Rising number of clinical trials of vascular grafts
  • Market Restraints
    • High treatment cost of vascular graft procedures
  • Market Opportunities
    • Improvements in the design and performance of vascular grafts
    • Development of tissue-engineered vascular grafts
  • Market Challenges
    • Infections associated with vascular grafts

Porter's Five Forces: A Strategic Tool for Navigating the Vascular Graft Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Vascular Graft Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Vascular Graft Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Vascular Graft Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Vascular Graft Market

A detailed market share analysis in the Vascular Graft Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Vascular Graft Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Vascular Graft Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Vascular Graft Market

A strategic analysis of the Vascular Graft Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Vascular Graft Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Affluent Medical, B. Braun Melsungen AG, Becton, Dickinson and Company, BIOVIC Sdn. Bhd., Boston Scientific Corporation, Cardinal Health Inc., Cook Medical, Inc., Corcym S.r.l., CryoLife, Inc., Endologix Inc., Getinge AB, Heart Medical Europe B.V., Japan Lifeline Co., Ltd., Lemaitre Vascular, Inc., Medtronic PLC, Merit Medical Systems, Inc., Perouse Medical SAS by Vygon SAS, Rua Life Sciences PLC, Shanghai Suokang Medical Implants Co. Ltd., Terumo Corporation, Vascular Graft Solutions Ltd., VUP Medical, W. L. Gore & Associates, Inc., and Xeltis B.V..

Market Segmentation & Coverage

This research report categorizes the Vascular Graft Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Raw Material, market is studied across Biological Materials, Polyester, Polytetrafluoroethylene, and Polyurethane. The Biological Materials is further studied across Human Saphenous & Umbilical Veins and Tissue Engineered Materials.
  • Based on Product, market is studied across Coronary Artery By-Pass Graft, Endovascular Stent Graft, Hemodialysis Access Graft, and Peripheral Vascular Graft.
  • Based on Application, market is studied across Aneurysm, Cardiovascular, Diabetes, Kidney Failure, and Vascular Occlusion.
  • Based on End-User, market is studied across Ambulatory Surgical Center and Hospital.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of lifestyle-related disorders globally
      • 5.1.1.2. Growing preference for minimally invasive procedures
      • 5.1.1.3. Rising number of clinical trials of vascular grafts
    • 5.1.2. Restraints
      • 5.1.2.1. High treatment cost of vascular graft procedures
    • 5.1.3. Opportunities
      • 5.1.3.1. Improvements in the design and performance of vascular grafts
      • 5.1.3.2. Development of tissue-engineered vascular grafts
    • 5.1.4. Challenges
      • 5.1.4.1. Infections associated with vascular grafts
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Raw Material: Burgeoning utilization of polytetrafluoroethylene-based vascular grafts owing to their biocompatibility and flexibility
    • 5.2.2. Product: Proliferating usage of peripheral vascular graft for restoring blood flow in patients with blockages in the peripheral arteries
    • 5.2.3. Application: Significant use of vascular grafts in treating cardiovascular diseases
    • 5.2.4. End-User: Significant applications of vascular grafts in ambulatory surgical centers (ASCs)
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Vascular Graft Market, by Raw Material

  • 6.1. Introduction
  • 6.2. Biological Materials
    • 6.2.1. Human Saphenous & Umbilical Veins
    • 6.2.2. Tissue Engineered Materials
  • 6.3. Polyester
  • 6.4. Polytetrafluoroethylene
  • 6.5. Polyurethane

7. Vascular Graft Market, by Product

  • 7.1. Introduction
  • 7.2. Coronary Artery By-Pass Graft
  • 7.3. Endovascular Stent Graft
  • 7.4. Hemodialysis Access Graft
  • 7.5. Peripheral Vascular Graft

8. Vascular Graft Market, by Application

  • 8.1. Introduction
  • 8.2. Aneurysm
  • 8.3. Cardiovascular
  • 8.4. Diabetes
  • 8.5. Kidney Failure
  • 8.6. Vascular Occlusion

9. Vascular Graft Market, by End-User

  • 9.1. Introduction
  • 9.2. Ambulatory Surgical Center
  • 9.3. Hospital

10. Americas Vascular Graft Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Vascular Graft Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Vascular Graft Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Aquedeon Medical, Inc. Receives FDA IDE Approval for the Duett Vascular Graft System
    • 13.3.2. Xeltis' aXess Vascular Graft Development Receives Funding From European Innovation Council
    • 13.3.3. Vygon Partners with Carmat to Develop a Vascular Graft for an Artificial Heart
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Affluent Medical
  • 3. B. Braun Melsungen AG
  • 4. Becton, Dickinson and Company
  • 5. BIOVIC Sdn. Bhd.
  • 6. Boston Scientific Corporation
  • 7. Cardinal Health Inc.
  • 8. Cook Medical, Inc.
  • 9. Corcym S.r.l.
  • 10. CryoLife, Inc.
  • 11. Endologix Inc.
  • 12. Getinge AB
  • 13. Heart Medical Europe B.V.
  • 14. Japan Lifeline Co., Ltd.
  • 15. Lemaitre Vascular, Inc.
  • 16. Medtronic PLC
  • 17. Merit Medical Systems, Inc.
  • 18. Perouse Medical SAS by Vygon SAS
  • 19. Rua Life Sciences PLC
  • 20. Shanghai Suokang Medical Implants Co. Ltd.
  • 21. Terumo Corporation
  • 22. Vascular Graft Solutions Ltd.
  • 23. VUP Medical
  • 24. W. L. Gore & Associates, Inc.
  • 25. Xeltis B.V.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦